Cardiol Therapeutics Inc (CRDL) Is A Buy According To Analysts

Cardiol Therapeutics Inc (NASDAQ:CRDL) has a beta value of 1.02 and has seen 0.7 million shares traded in the recent trading session. The company, currently valued at $175.95M, closed the recent trade at $2.55 per share which meant it gained $0.14 on the day or 5.81% during that session. The CRDL stock price is -10.2% off its 52-week high price of $2.81 and 74.12% above the 52-week low of $0.66. The 3-month trading volume is 337.49K shares.

Cardiol Therapeutics Inc (NASDAQ:CRDL) trade information

Sporting 5.81% in the green today, the stock has traded in the red over the last five days, when the CRDL stock price touched $2.55 or saw a rise of 9.25%. Year-to-date, Cardiol Therapeutics Inc shares have moved 202.42%, while the 5-day performance has seen it change -8.27%. Over the past 30 days, the shares of Cardiol Therapeutics Inc (NASDAQ:CRDL) have changed 15.38%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Cardiol Therapeutics Inc (CRDL) estimates and forecasts

Figures show that Cardiol Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 174.90% over the past 6 months, with this year growth rate of 21.21%, compared to 14.30% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 16.52% over the past 5 years.

CRDL Dividends

Cardiol Therapeutics Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.